Clinical Trial Update: Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update reports the completion of a Phase 1/2 study evaluating Talimogene laherparepvec with neoadjuvant chemotherapy for triple-negative breast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Invasive Ductal Carcinoma of the Breast
• Triple-negative Breast Cancer

Drugs mentioned

• Talimogene laherparepvec (talimogene laherparepvec)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Breast Cancer, Ductal Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-10-28